| Characteristic . | n = 93 . | |
|---|---|---|
| Age (years), median (range) | 79 (21-90) | |
| <75 years | 31 | 33% |
| ≥75 years | 62 | 67% |
| Sex | ||
| Male | 49 | 53% |
| Female | 44 | 47% |
| ECOG performance status | ||
| 0 | 23 | 25% |
| 1 | 60 | 65% |
| 2 | 10 | 11% |
| Location of primary tumor | ||
| Right-sided | 28 | 30% |
| Left-sided | 65 | 70% |
| Primary tumor resection | ||
| Yes | 80 | 86% |
| No | 13 | 14% |
| Pre- or postoperative chemotherapy | ||
| Yes | 35 | 38% |
| No | 58 | 62% |
| Prior chemotherapy agent for metastatic disease | ||
| Fluoropyrimidine | 93 | 100% |
| Oxaliplatin | 46 | 49% |
| Irinotecan | 14 | 15% |
| Antiangiogenic antibodies | 84 | 90% |
| Anti-EGFR antibodies | 18 | 19% |
| Treatment line | ||
| Second | 74 | 80% |
| Third or fourth | 19 | 20% |
| RAS status | ||
| Wild type | 32 | 34% |
| Mutant | 59 | 63% |
| Unknown | 2 | 2% |
| BRAF status | ||
| Wild type | 46 | 49% |
| Mutant | 1 | 1% |
| Unknown | 46 | 49% |
| MSI/MMR status | ||
| MSI-high or MMR-deficient | 3 | 3% |
| MSS or MMR-proficient | 56 | 60% |
| Unknown | 34 | 37% |
| Characteristic . | n = 93 . | |
|---|---|---|
| Age (years), median (range) | 79 (21-90) | |
| <75 years | 31 | 33% |
| ≥75 years | 62 | 67% |
| Sex | ||
| Male | 49 | 53% |
| Female | 44 | 47% |
| ECOG performance status | ||
| 0 | 23 | 25% |
| 1 | 60 | 65% |
| 2 | 10 | 11% |
| Location of primary tumor | ||
| Right-sided | 28 | 30% |
| Left-sided | 65 | 70% |
| Primary tumor resection | ||
| Yes | 80 | 86% |
| No | 13 | 14% |
| Pre- or postoperative chemotherapy | ||
| Yes | 35 | 38% |
| No | 58 | 62% |
| Prior chemotherapy agent for metastatic disease | ||
| Fluoropyrimidine | 93 | 100% |
| Oxaliplatin | 46 | 49% |
| Irinotecan | 14 | 15% |
| Antiangiogenic antibodies | 84 | 90% |
| Anti-EGFR antibodies | 18 | 19% |
| Treatment line | ||
| Second | 74 | 80% |
| Third or fourth | 19 | 20% |
| RAS status | ||
| Wild type | 32 | 34% |
| Mutant | 59 | 63% |
| Unknown | 2 | 2% |
| BRAF status | ||
| Wild type | 46 | 49% |
| Mutant | 1 | 1% |
| Unknown | 46 | 49% |
| MSI/MMR status | ||
| MSI-high or MMR-deficient | 3 | 3% |
| MSS or MMR-proficient | 56 | 60% |
| Unknown | 34 | 37% |
Values are n (%) with the exception of median (range) age.
Abbreviaitons: ECOG: Eastern Cooperative Oncology Group; EGFR: epidermal growth factor receptor; MSI, microsatellite instability; MMR, mismatch repair; MSS, microsatellite stable.
| Characteristic . | n = 93 . | |
|---|---|---|
| Age (years), median (range) | 79 (21-90) | |
| <75 years | 31 | 33% |
| ≥75 years | 62 | 67% |
| Sex | ||
| Male | 49 | 53% |
| Female | 44 | 47% |
| ECOG performance status | ||
| 0 | 23 | 25% |
| 1 | 60 | 65% |
| 2 | 10 | 11% |
| Location of primary tumor | ||
| Right-sided | 28 | 30% |
| Left-sided | 65 | 70% |
| Primary tumor resection | ||
| Yes | 80 | 86% |
| No | 13 | 14% |
| Pre- or postoperative chemotherapy | ||
| Yes | 35 | 38% |
| No | 58 | 62% |
| Prior chemotherapy agent for metastatic disease | ||
| Fluoropyrimidine | 93 | 100% |
| Oxaliplatin | 46 | 49% |
| Irinotecan | 14 | 15% |
| Antiangiogenic antibodies | 84 | 90% |
| Anti-EGFR antibodies | 18 | 19% |
| Treatment line | ||
| Second | 74 | 80% |
| Third or fourth | 19 | 20% |
| RAS status | ||
| Wild type | 32 | 34% |
| Mutant | 59 | 63% |
| Unknown | 2 | 2% |
| BRAF status | ||
| Wild type | 46 | 49% |
| Mutant | 1 | 1% |
| Unknown | 46 | 49% |
| MSI/MMR status | ||
| MSI-high or MMR-deficient | 3 | 3% |
| MSS or MMR-proficient | 56 | 60% |
| Unknown | 34 | 37% |
| Characteristic . | n = 93 . | |
|---|---|---|
| Age (years), median (range) | 79 (21-90) | |
| <75 years | 31 | 33% |
| ≥75 years | 62 | 67% |
| Sex | ||
| Male | 49 | 53% |
| Female | 44 | 47% |
| ECOG performance status | ||
| 0 | 23 | 25% |
| 1 | 60 | 65% |
| 2 | 10 | 11% |
| Location of primary tumor | ||
| Right-sided | 28 | 30% |
| Left-sided | 65 | 70% |
| Primary tumor resection | ||
| Yes | 80 | 86% |
| No | 13 | 14% |
| Pre- or postoperative chemotherapy | ||
| Yes | 35 | 38% |
| No | 58 | 62% |
| Prior chemotherapy agent for metastatic disease | ||
| Fluoropyrimidine | 93 | 100% |
| Oxaliplatin | 46 | 49% |
| Irinotecan | 14 | 15% |
| Antiangiogenic antibodies | 84 | 90% |
| Anti-EGFR antibodies | 18 | 19% |
| Treatment line | ||
| Second | 74 | 80% |
| Third or fourth | 19 | 20% |
| RAS status | ||
| Wild type | 32 | 34% |
| Mutant | 59 | 63% |
| Unknown | 2 | 2% |
| BRAF status | ||
| Wild type | 46 | 49% |
| Mutant | 1 | 1% |
| Unknown | 46 | 49% |
| MSI/MMR status | ||
| MSI-high or MMR-deficient | 3 | 3% |
| MSS or MMR-proficient | 56 | 60% |
| Unknown | 34 | 37% |
Values are n (%) with the exception of median (range) age.
Abbreviaitons: ECOG: Eastern Cooperative Oncology Group; EGFR: epidermal growth factor receptor; MSI, microsatellite instability; MMR, mismatch repair; MSS, microsatellite stable.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
